Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
The clinical success of restoring P53 for cancer therapy has been limited due to toxicity. Here, the authors identify USP2 as an upstream regulator of VPRBP-mediated degradation of p53 and PD-L1 and demonstrate the efficacy of combining USP2 inhibitor and PD-L1/PD-1 immune checkpoint blockade in can...
Main Authors: | Jingjie Yi, Omid Tavana, Huan Li, Donglai Wang, Richard J. Baer, Wei Gu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-37617-3 |
Similar Items
-
VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate cancer
by: Poulose, N, et al.
Published: (2022) -
Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1
by: Jia Wen, et al.
Published: (2023-07-01) -
Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
by: Si-Min Qi, et al.
Published: (2020-04-01) -
The CRL4VPRBP(DCAF1) E3 ubiquitin ligase directs constitutive RAG1 degradation in a non-lymphoid cell line.
by: N Max Schabla, et al.
Published: (2021-01-01) -
53BP1 and USP28 mediate p53-dependent cell cycle arrest in response to centrosome loss and prolonged mitosis
by: Chii Shyang Fong, et al.
Published: (2016-07-01)